×
About 51,630 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  24,439 results

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytar...
https://doi.org/10.3324/haematol.2020.263392
Haematologica Swaminathan M, Kantarjian HM et. al.

Apr 15th, 2021 - FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation in acute myeloid leukemia (AML) is associated with poor prognosis. We hypothesized that quizartinib, a selective and potent FLT3 inhibitor, with azacitidine (AZA) or low-do...

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to veneto...
https://doi.org/10.3324/haematol.2020.272609
Haematologica Cojocari D, Smith BN et. al.

Apr 15th, 2021 - Dysregulation of apoptotic machinery is one mechanism by which acute myeloid leukemia (AML) acquires a clonal survival advantage. B-cell lymphoma protein-2 (BCL2) overexpression is a common feature in hematologic malignancies. The selective BCL2 i...

The development and clinical use of oral hypomethylating agents in acute myeloid leukem...
https://doi.org/10.1080/14737140.2021.1918002
Expert Review of Anticancer Therapy; Schiffer M, Zhao J et. al.

Apr 15th, 2021 - Intravenous and subcutaneous hypomethylating agents have held a key role in myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia treatment. Following the approval of the cedazuridine/decitabine combination, ASTX727,...

The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/r...
https://doi.org/10.1080/14740338.2021.1913120
Expert Opinion on Drug Safety; Marconi G, Giannini MB et. al.

Apr 15th, 2021 - FLT3 inhibitors are important drugs in the therapy of FLT3 positive acute myeloid leukemia (AML). Midostaurin was registered in combination with chemotherapy to treat newly diagnosed AML. Gilteritinib and quizartinib demonstrate effectiveness in a...

The shape of low-concentration dose-response functions for benzene: implications for hu...
https://doi.org/10.1080/10408444.2020.1860903
Critical Reviews in Toxicology; Cox LA, Ketelslegers HB et. al.

Apr 15th, 2021 - Are dose-response relationships for benzene and health effects such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) supra-linear, with disproportionately high risks at low concentrations, e.g. below 1 ppm? To investigate this hy...

see more →

Guidelines  95 results

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 23rd, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Ivosidenib Plus Venetoclax With or Without Azacitidine for IDH1-Mutated AML
https://ascopost.com/news/june-2020/ivosidenib-plus-venetoclax-with-or-without-azacitidine-for-idh1-mutated-aml/

May 31st, 2020 - Combination therapy with the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosenidib plus the BCL2 inhibitor venetoclax with or without the chemotherapeutic agent azacitidine showed activity in patients with IDH1-mutated acute myeloid leukemia (AML...

AMG 330 Shows Promise in Treating Relapsed/Refractory AML
https://www.onclive.com/conference-coverage/asco-2020/amg-330-shows-promise-in-treating-relapsedrefractory-aml

May 29th, 2020 - Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia (AML), with cytokine release syndrome (CRS) as the most frequent and expected adverse event (AE), according to preliminary ...

Palliative Care Improves Quality of Life in Patients With AML
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200172/full/

May 28th, 2020 - When patients with acute myeloid leukemia (AML) undergo intensive chemotherapy treatment, their quality of life (QoL) and mood are negatively affected. Areej El-Jawahri, MD, of Massachusetts General Hospital, presented the results of a multicenter...

High Expression of DOCK2 Indicates Good Prognosis in AML
https://www.jcancer.org/v10p6088.htm
Journal of Cancer; Hu N,et al

Oct 14th, 2019 - DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse prognostic effect in acute myeloid leukemia (AML).

see more →

Drugs  59 results see all →

Clinicaltrials.gov  25,535 results

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytar...
https://doi.org/10.3324/haematol.2020.263392
Haematologica Swaminathan M, Kantarjian HM et. al.

Apr 15th, 2021 - FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation in acute myeloid leukemia (AML) is associated with poor prognosis. We hypothesized that quizartinib, a selective and potent FLT3 inhibitor, with azacitidine (AZA) or low-do...

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to veneto...
https://doi.org/10.3324/haematol.2020.272609
Haematologica Cojocari D, Smith BN et. al.

Apr 15th, 2021 - Dysregulation of apoptotic machinery is one mechanism by which acute myeloid leukemia (AML) acquires a clonal survival advantage. B-cell lymphoma protein-2 (BCL2) overexpression is a common feature in hematologic malignancies. The selective BCL2 i...

The development and clinical use of oral hypomethylating agents in acute myeloid leukem...
https://doi.org/10.1080/14737140.2021.1918002
Expert Review of Anticancer Therapy; Schiffer M, Zhao J et. al.

Apr 15th, 2021 - Intravenous and subcutaneous hypomethylating agents have held a key role in myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia treatment. Following the approval of the cedazuridine/decitabine combination, ASTX727,...

The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/r...
https://doi.org/10.1080/14740338.2021.1913120
Expert Opinion on Drug Safety; Marconi G, Giannini MB et. al.

Apr 15th, 2021 - FLT3 inhibitors are important drugs in the therapy of FLT3 positive acute myeloid leukemia (AML). Midostaurin was registered in combination with chemotherapy to treat newly diagnosed AML. Gilteritinib and quizartinib demonstrate effectiveness in a...

The shape of low-concentration dose-response functions for benzene: implications for hu...
https://doi.org/10.1080/10408444.2020.1860903
Critical Reviews in Toxicology; Cox LA, Ketelslegers HB et. al.

Apr 15th, 2021 - Are dose-response relationships for benzene and health effects such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) supra-linear, with disproportionately high risks at low concentrations, e.g. below 1 ppm? To investigate this hy...

see more →

News  1,495 results

Whole-Genome Sequencing Emerging for Routine Cancer Care
https://www.medscape.com/viewarticle/947261

Mar 10th, 2021 - Almost 20 years after the human genome was first mapped, whole-genome sequencing might finally be ready to enter routine cancer care. Researchers at Washington University in St. Louis, St. Louis, Missouri, are commercializing an automated sequenci...

FDA Places Clinical Hold on Sickle Cell Gene Therapy
https://www.medscape.com/viewarticle/946434

Feb 23rd, 2021 - Updated February 25, 2021 // Editor’s note: The original text has been corrected to accurately reflect the status of the patients with AML and MDS. The FDA placed a clinical hold yesterday on two gene therapy trials for sickle cell disease (SCD) a...

Fast Five Quiz: Myelodysplastic Syndrome
https://reference.medscape.com/viewarticle/943967

Jan 27th, 2021 - Myelodysplastic syndrome (MDS) is a group of related hematopoietic disorders characterized by peripheral blood cytopenias, abnormal blood cell development, and clonal genetic markers. Patients with MDS may present with clinical manifestations of a...

Leukemia: New Adverse Event With PARP Inhibitors in Cancer
https://www.medscape.com/viewarticle/943743

Jan 6th, 2021 - A new adverse event has been reported for PARP inhibitor drugs used in the treatment of cancer: the risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), both of which have a high mortality rate.   PARP inhibitors are...

Black Race Linked to Poorer Survival in AML
https://www.medscape.com/viewarticle/942309

Dec 8th, 2020 - Black race is the most important risk factor for patients with acute myeloid leukemia (AML) and is associated with poor survival, according to new findings. Among patients with AML younger than 60 years, the rate of overall 3-year survival was sig...

see more →

Patient Education  7 results see all →